Company:  GENFIT S.A. (GNFT)
Form Type:  6-K
Filing Date:  4/15/2019 
CIK:  0001757064 
City, State, Zip:  LOOS,  59120 
Telephone:  33 3 20 16 4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
-0.16 (-1.07%)  
Trade Time: 
Oct 17  
Market Cap: 
Trade GNFT now with

© 2019  
Description of Business
We are a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions targeting metabolic and liver-related diseases where there is considerable unmet medical need. We are a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. We are evaluating our most advanced drug candidate, elafibranor, in a pivotal Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, or NASH, and as a potential treatment for primary biliary cholangitis, or PBC. In December 2018, we announced positive preliminary results from our Phase 2 clinical trial in PBC. Our drug discovery efforts are based on selecting appropriate nuclear receptors as targets and utilizing rational drug design to optimize our drug candidates.
Register and access this filing in:     
  FORM 6-K
  EXHIBIT 99.1